Governance Arcus Biosciences, Inc.

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 21:00:02 10/06/2026 BST			5-day change	1st Jan Change
22.12 ^USD	-6.43%		-7.29%	-7.18%

06-10	Arcus Biosciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:40 AM
06-03	Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment	MT

Executive Committee: Arcus Biosciences, Inc.

Manager

Positions heldSince

Terry Rosen

68 year

Chief Executive Officer	30/04/2015
Founder	31/12/2014

Jonathan Yingling

57 year

Chief Tech/Sci/R&D Officer

30/09/2020

Pia Eaves

Investor Relations Contact

31/01/2024

Richard Markus

61 year

Chief Tech/Sci/R&D Officer

30/01/2025

Alexander Azoy

50 year

Comptroller/Controller/Auditor

08/03/2023

Carolyn Tang

48 year

General Counsel

30/06/2017

Yvonne Gehring

Human Resources Officer

31/12/2015

Steve Young

57 year

Chief Tech/Sci/R&D Officer

29/02/2016

Robert Goeltz

54 year

Director of Finance/CFO

31/07/2020

Juan Jaen

69 year

Founder	31/12/2014
President	30/04/2015

Composition of the Board of Directors: Arcus Biosciences, Inc.

Director

CommitteesSince

Terry Rosen

68 year

Compensation Committee
Governance Committee Chair
Nominating Committee Chair

Clarence Machado

63 year

Compensation Committee	04/11/2020
Audit Committee Chair	20/06/2024
Governance Committee	20/06/2024
Nominating Committee	20/06/2024
Audit Committee	11/01/2021

David Lacey

73 year

Compensation Committee Chair
Compensation Committee	28/02/2023
Governance Committee Chair	28/02/2023
Nominating Committee Chair	28/02/2023

Nicole Lambert

74 year

Compensation Committee	28/02/2025
Governance Committee	28/02/2023
Nominating Committee	28/02/2023

Yasunori Kaneko

71 year

Audit Committee	30/04/2015
Compensation Committee Chair	30/04/2015

Johanna Mercier

57 year

Governance Committee	14/04/2021
Nominating Committee	14/04/2021

Kathryn Falberg

66 year

Audit Committee Chair

30/09/2020

Andrew Perlman

79 year

Audit Committee

15/04/2021

Linda Higgins

64 year

Director/Board Member

09/08/2021

Antoni Ribas

61 year

Director/Board Member	27/10/2019
Independent Dir/Board Member	27/10/2019

Dietmar Berger

64 year

Director/Board Member

05/02/2025

Latest Appointments: Arcus Biosciences, Inc.

05-04	Pasithea Therapeutics Corp. Appoints Kartik Krishnan as Chief Medical Officer, Effective May 1, 2026	CI
04-07	Tuhura Biosciences, Inc. Appoints Amanda Garofalo as Senior Vice President of Clinical Operations	CI
03-23	Damora Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective March 30, 2026	CI
03-23	Damora Therapeutics, Inc. Announces Executive and Board Changes	CI
03-23	Arcus Biosciences, Inc. Announces Resignation of Jennifer Jarrett as Chief Operating Officer, Effective March 30, 2026	CI
06/02/25	Arcus Biosciences, Inc. Announces Board Changes	CI
21/01/25	Arcus Biosciences Appoints Richard Markus as Medical Chief	MT

More news

Former Officers and Directors: Arcus Biosciences, Inc.

Insider

Positions held

SinceUntil

Jennifer Jarrett

Director/Board Member	11/01/2019	28/01/2024
Chief Operating Officer	30/09/2020	29/03/2026
Director of Finance/CFO	28/02/2017	11/01/2019

Eric Matthews

Corporate Officer/Principal

23/06/2019

31/03/2025

Merdad Parsey

Director/Board Member

12/07/2020

05/02/2025

Dimitry Nuyten

Chief Tech/Sci/R&D Officer

31/07/2022

30/01/2025

Melissa C. Paoloni

Chief Tech/Sci/R&D Officer	31/01/2019	-
Corporate Officer/Principal	-	31/10/2023

Nick Giafis

Chief Tech/Sci/R&D Officer

31/05/2020

31/05/2023

Patricia Carlos

General Counsel

31/08/2019

31/08/2022

Kartik Krishnan

Chief Tech/Sci/R&D Officer

30/09/2019

31/07/2022

Michael Quigley

Director/Board Member	05/01/2021	09/08/2021
Independent Dir/Board Member	05/01/2021	09/08/2021

William Grossman

Chief Tech/Sci/R&D Officer

01/05/2019

15/07/2021

Jason Barker

Comptroller/Controller/Auditor	29/09/2019	31/07/2020
Director of Finance/CFO	29/09/2019	31/07/2020
Corporate Officer/Principal	30/04/2019	29/09/2019

Timothy Sullivan

Corporate Officer/Principal

31/12/2016

30/04/2020

Kristen Hege

Director/Board Member	21/10/2018	19/11/2019
Independent Dir/Board Member	-	19/11/2019

Rekha Hemrajani

Chief Operating Officer	25/03/2019	29/09/2019
Director of Finance/CFO	25/03/2019	29/09/2019

Katherine Bock

Investor Relations Contact

31/03/2019

Steven Chan

Comptroller/Controller/Auditor

31/03/2017

31/03/2019

Nicole Arndt

Investor Relations Contact

28/02/2018

David Beier

Director/Board Member	17/12/2017	-
Independent Dir/Board Member	17/12/2017	-

Joyson Karakunnel

Chief Tech/Sci/R&D Officer

31/03/2017

Anupama Hoey

Corporate Officer/Principal

31/10/2015

30/11/2016

Pia Banerjee

Investor Relations Contact

Age distribution of managers

Parity Men Women

Male	15
Female	7

Of which Executive Committee

Male	7
Female	3

Of which Directors

Male	8
Female	3

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Employees

601

Sector

Biotechnology & Medical Research

More about the company